Circulation reports最新文献_第5页

Phase 2 Study to Evaluate the Efficacy and Safety of Inhaled Nitric Oxide Therapy in Patients With Severe Right Heart Failure Associated With Pulmonary Hypertension　- Protocol for the PHiNO Study. 评估吸入一氧化氮治疗严重右心衰伴肺动脉高压患者的有效性和安全性的2期研究- PHiNO研究方案

Circulation reports Pub Date : 2025-02-11 eCollection Date: 2025-04-10 DOI: 10.1253/circrep.CR-24-0125

Jin Ueda, Akihiro Tsuji, Tatsuo Aoki, Ryotaro Asano, Takatoyo Kiko, Hiroya Hayashi, Hiroyuki Endo, Naruhiro Nishi, Ryo Takano, Shinya Fujisaki, Mitsumasa Akao, Koko Asakura, Haruko Yamamoto, Takeshi Ogo

{"title":"Phase 2 Study to Evaluate the Efficacy and Safety of Inhaled Nitric Oxide Therapy in Patients With Severe Right Heart Failure Associated With Pulmonary Hypertension　- Protocol for the PHiNO Study.","authors":"Jin Ueda, Akihiro Tsuji, Tatsuo Aoki, Ryotaro Asano, Takatoyo Kiko, Hiroya Hayashi, Hiroyuki Endo, Naruhiro Nishi, Ryo Takano, Shinya Fujisaki, Mitsumasa Akao, Koko Asakura, Haruko Yamamoto, Takeshi Ogo","doi":"10.1253/circrep.CR-24-0125","DOIUrl":"https://doi.org/10.1253/circrep.CR-24-0125","url":null,"abstract":"Background: Acute right heart failure (RHF) is a syndrome characterized by sudden right ventricular dysfunction leading to systemic hypoperfusion, which carries a poor prognosis, particularly in patients with pulmonary hypertension (PH). Early reduction of pulmonary vascular resistance (PVR) is crucial for improving RHF and reducing acute mortality. Compared with pulmonary vasodilators approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic PH (CTEPH), inhaled nitric oxide (iNO) therapy has the advantages of being fast acting, an excellent selective pulmonary vasodilation, and has less effect on systemic blood pressure.Methods and results: We describe a phase II, investigator-initiated, randomized, open-label trial (Japan Registry of Clinical Trials jRCT2051220042) to evaluate the efficacy and safety of iNO therapy (INOflo® for inhalation 800 ppm), as an acute-phase treatment for severe RHF associated with PAH or CTEPH over a 1-week course. Thirty patients will be enrolled and randomized to receive the study drug, or not, in addition to conventional therapy. The primary endpoint is the change in PVR from baseline to 30 min after the start of inhalation, measured using right heart catheterization. Secondary endpoints include changes in hemodynamic parameters, arterial blood tests, and echocardiography findings, and the safety of iNO therapy, assessed through blood methemoglobin concentration, blood pressure, and adverse events.Conclusions: iNO therapy is expected to play a significant role in rapidly improving acute severe RHF associated with PH.","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 4","pages":"308-312"},"PeriodicalIF":0.0,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11981675/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic Value of B-Type Natriuretic Peptide Level in Patients With Heart Failure With a Higher Left Ventricular Ejection Fraction. b型利钠肽水平对左心室射血分数较高的心力衰竭患者的预后价值。

Circulation reports Pub Date : 2025-02-08 eCollection Date: 2025-03-10 DOI: 10.1253/circrep.CR-24-0172

Nobuyuki Ohte, Shohei Kikuchi, Noriaki Iwahashi, Yoshiharu Kinugasa, Kaoru Dohi, Hiroyuki Takase, Katsuji Inoue, Takahiro Okumura, Kenta Hachiya, Emiyo Sugiura, Kenya Kusunose, Shuichi Kitada, Yoshihiro Seo

{"title":"Prognostic Value of B-Type Natriuretic Peptide Level in Patients With Heart Failure With a Higher Left Ventricular Ejection Fraction.","authors":"Nobuyuki Ohte, Shohei Kikuchi, Noriaki Iwahashi, Yoshiharu Kinugasa, Kaoru Dohi, Hiroyuki Takase, Katsuji Inoue, Takahiro Okumura, Kenta Hachiya, Emiyo Sugiura, Kenya Kusunose, Shuichi Kitada, Yoshihiro Seo","doi":"10.1253/circrep.CR-24-0172","DOIUrl":"10.1253/circrep.CR-24-0172","url":null,"abstract":"Background: In heart failure (HF) patients with a higher left ventricular ejection fraction (LVEF), the B-type natriuretic peptide (BNP) level is yet to be fully assessed. Accordingly, we hypothesized that the BNP level should be higher in patients with a higher LVEF range based on the previous finding that such patients were associated with a worse prognosis.Methods and results: In our multicenter, prospective, observational cohort for the composite endpoint of all-cause death and readmission due to HF, including patients with LVEF >40% at hospital discharge, we obtained LVEF, E/e', and BNP levels in 231 patients. The concurrent atrial fibrillation (AF) was confirmed by electrocardiogram. Patients were divided into HF with mildly reduced EF (HFmrEF), HF with preserved EF (HFpEF) with LVEF ≥50 and <60%, and HFpEF with LVEF ≥60%. The BNP levels were not significantly different among these groups (median [interquartile range]: 195 [110-348] vs. 242 [150-447] vs. 220 [125-320] pg/mL, respectively; P=0.422). In contrast, a BNP level of ≥377 pg/mL could significantly differentiate event-free survival (P<0.001). In the multi-covariate Cox proportional hazards model, the BNP level was significantly related to event-free survival independent of LVEF, E/e', and concurrent AF.Conclusions: Without confounding the effects of LVEF, E/e', and concurrent AF, higher BNP levels are significantly and independently associated with event-free survival in HF patients with LVEF>40%.","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 3","pages":"191-197"},"PeriodicalIF":0.0,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890284/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Features of Acute on Chronic Lower Limb Ischemia and the Importance of Underlying Arterial Disease for Revascularization. 急性和慢性下肢缺血的临床特点及基础动脉疾病对血运重建的重要性。

Circulation reports Pub Date : 2025-02-07 eCollection Date: 2025-03-10 DOI: 10.1253/circrep.CR-24-0173

Tsutomu Doita, Shinsuke Kikuchi, Yuya Tamaru, Takayuki Uramoto, Kazuki Takahashi, Keisuke Kamada, Seima Ohira, Hiroya Moriyama, Takamitsu Tatsukawa, Naoya Kuriyama, Yuri Yoshida, Daiki Uchida, Keisuke Miyake, Shigeru Miyagawa, Nobuyoshi Azuma

{"title":"Clinical Features of Acute on Chronic Lower Limb Ischemia and the Importance of Underlying Arterial Disease for Revascularization.","authors":"Tsutomu Doita, Shinsuke Kikuchi, Yuya Tamaru, Takayuki Uramoto, Kazuki Takahashi, Keisuke Kamada, Seima Ohira, Hiroya Moriyama, Takamitsu Tatsukawa, Naoya Kuriyama, Yuri Yoshida, Daiki Uchida, Keisuke Miyake, Shigeru Miyagawa, Nobuyoshi Azuma","doi":"10.1253/circrep.CR-24-0173","DOIUrl":"10.1253/circrep.CR-24-0173","url":null,"abstract":"Background: Acute lower extremity limb ischemia (ALI) is a common vascular surgery emergency, primarily caused by embolism or atherosclerotic in situ thrombosis-acute on chronic limb ischemia (AoCLI). This study aimed to examine the clinical features and treatment challenges of AoCLI.Methods and results: Between January 2014 and December 2022, 73 patients with AoCLI (n=35) or embolic ALI (n=38) were analyzed. The time from ALI onset was significantly longer (P<0.01), and the rate of contralateral diseases was higher in AoCLI than embolic ALI (P<0.01). Treatment and intraoperative findings showed higher rates of failed thrombectomy (P=0.027), difficulty in crossing lesions (P<0.01), defined as failure of Fogarty catheter crossing despite guidewire navigation and requirement of the balloon angioplasty for the lesions, additional revascularization (P<0.01), and multi-segment treatment (P<0.01) in AoCLI. In multivariate analysis, unfavorable factors for endovascular therapy (EVT) were >2.5 days from ALI onset (odds ratio [OR] 1.4; 95% confidence interval [CI] 1.0-2.0), non-atrial fibrillation (OR 4.2; 95% CI 1.0-16.7), and collateral development (OR 9.0; 95% CI 1.0-81.5). Rates of failed EVT were 0% for no factors, 18% for 1 factor, 43% for 2 factors, and 90% for 3 factors.Conclusions: AoCLI had more complex and multi-segment arterial lesions, making limb perfusion restoration difficult. The unfavorable factors for EVT could help stratify the optimal treatment of ALI in emergency settings.","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 3","pages":"168-175"},"PeriodicalIF":0.0,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890296/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cross-Sectional Study Demonstrating Specificity of Iron Kinetics in Atrial Fibrillation. 横断面研究证明心房颤动铁动力学的特异性。

Circulation reports Pub Date : 2025-02-06 eCollection Date: 2025-03-10 DOI: 10.1253/circrep.CR-24-0123

Takahiro Kamihara, Shinji Kaneko, Takuya Omura, Kenta Motegi, Akihiro Hirashiki, Manabu Kokubo, Atsuya Shimizu

{"title":"Cross-Sectional Study Demonstrating Specificity of Iron Kinetics in Atrial Fibrillation.","authors":"Takahiro Kamihara, Shinji Kaneko, Takuya Omura, Kenta Motegi, Akihiro Hirashiki, Manabu Kokubo, Atsuya Shimizu","doi":"10.1253/circrep.CR-24-0123","DOIUrl":"10.1253/circrep.CR-24-0123","url":null,"abstract":"Background: In the context of cardiovascular disease (CVD), iron metabolism assessment plays a pivotal role in the diagnosis of anemia and chronic inflammation. However, data regarding the prevalence of anemia, iron deficiency, and iron overload among outpatients in real-world clinical settings remain limited. Moreover, the influence of specific diseases on iron kinetics within the CVD spectrum has not been fully elucidated.Methods and results: We conducted a retrospective analysis of 260 patients attending a cardiology outpatient clinic who had undergone blood sampling for comprehensive evaluation of anemia and iron kinetics. The prevalence of anemia among these outpatients was 36.1%, but iron deficiency was observed in only 13.8% of patients (absolute iron deficiency: 1.5%). Notably, stored iron positively correlated with free iron in patients with sinus rhythm, but not in patients with atrial fibrillation (AF). Intriguingly, this relationship followed a similar pattern in the paroxysmal and longstanding AF subgroups. Moreover, multivariate regression analysis showed that iron dynamics significantly explained hemoglobin levels in patients with sinus rhythm but not in those with AF.Conclusions: Although chronic inflammation may be a contributing factor, iron dynamics exhibited a distinct profile in patients with AF. The correlation between transferrin saturation and stored iron, evident in sinus rhythm patients, was abolished in AF, which supports the notion of chronic inflammation in patients with AF.","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 3","pages":"160-167"},"PeriodicalIF":0.0,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890283/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pulmonary Artery Denervation for Medication Refractory Pulmonary Hypertension (PARPH Study)　- Study Protocol for a Prospective, Open-Label, Single-Arm Clinical Trial. 肺动脉去神经支配治疗难治性肺动脉高压（PARPH研究）——一项前瞻性、开放标签、单臂临床试验的研究方案。

Circulation reports Pub Date : 2025-02-05 eCollection Date: 2025-03-10 DOI: 10.1253/circrep.CR-24-0179

Ryotaro Asano, Satoshi Nagase, Tatsuo Aoki, Jin Ueda, Akihiro Tsuji, Koko Asakura, Mayumi Fukuda-Doi, Yuko Inoue, Kengo Kusano, Haruko Yamamoto, Takeshi Ogo

{"title":"Pulmonary Artery Denervation for Medication Refractory Pulmonary Hypertension (PARPH Study)　- Study Protocol for a Prospective, Open-Label, Single-Arm Clinical Trial.","authors":"Ryotaro Asano, Satoshi Nagase, Tatsuo Aoki, Jin Ueda, Akihiro Tsuji, Koko Asakura, Mayumi Fukuda-Doi, Yuko Inoue, Kengo Kusano, Haruko Yamamoto, Takeshi Ogo","doi":"10.1253/circrep.CR-24-0179","DOIUrl":"10.1253/circrep.CR-24-0179","url":null,"abstract":"Background: Despite the development of effective pulmonary vasodilators, the prognosis for patients with pulmonary hypertension (PH) remains poor, particularly in medication-refractory patients. Catheter-based pulmonary artery denervation (PADN) is an emerging therapeutic strategy targeting the sympathetic nervous system in various types of PH. However, data on its safety and efficacy in refractory patients with PH who truly require non-pharmacotherapy are lacking. Here, we describe a phase II, investigator-initiated, open-label, single-arm trial (Japan Registry of Clinical Trials jRCTs052200017) to evaluate the efficacy and safety of PADN over a 2-year observation period.Methods and results: Twenty participants will be enrolled and will undergo PADN. The primary endpoint is the time from PADN to the first occurrence of the composite events of death, lung transplantation, and worsening of PH. The safety endpoints are the occurrence of adverse events related to PADN and bradycardia requiring treatment. The exploratory endpoints include right ventricular function evaluated using cardiac magnetic resonance imaging and Short Form-36 score.Conclusions: The findings of this study will lead to the adoption of PADN for patients with limited treatment options.","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 3","pages":"212-215"},"PeriodicalIF":0.0,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prefectural Survey on Immune Checkpoint Inhibitor-Associated Myocarditis at the Start of the Basic Plan to Promote Cancer Control Programs - Phase 4. 在促进癌症控制项目基本计划启动时免疫检查点抑制剂相关心肌炎的县域调查-第4期

Circulation reports Pub Date : 2025-02-04 eCollection Date: 2025-03-10 DOI: 10.1253/circrep.CR-24-0171

Yuji Okura, Satoru Miura, Naohito Tanabe, Kazuyuki Ozaki, Takeshi Kashimura, Akira Kikuchi, Tatsuya Takenouchi, Hiroshi Tanaka, Yasuo Saijo, Takayuki Inomata

{"title":"Prefectural Survey on Immune Checkpoint Inhibitor-Associated Myocarditis at the Start of the Basic Plan to Promote Cancer Control Programs - Phase 4.","authors":"Yuji Okura, Satoru Miura, Naohito Tanabe, Kazuyuki Ozaki, Takeshi Kashimura, Akira Kikuchi, Tatsuya Takenouchi, Hiroshi Tanaka, Yasuo Saijo, Takayuki Inomata","doi":"10.1253/circrep.CR-24-0171","DOIUrl":"10.1253/circrep.CR-24-0171","url":null,"abstract":"Background: In 2023, collaboration between cardiologists and oncologists was recommended as part of Japan's Basic Plan to Promote Disease Control Programs for both cancer and cardiovascular diseases. This study explores the extent of this collaboration in Niigata Prefecture.Methods and results: Self-administered questionnaires about immune checkpoint inhibitor-associated myocarditis (ICIAM) and anthracycline-related cardiomyopathy (ARCM) were distributed to all cardiologists and leading oncologists in hospitals across the Prefecture, of whom 124 cardiologists and 41 oncologists across 29 hospitals responded. Clinical experience with ICIAM was reported by 31.8% of cardiologists and 24.4% of leading oncologists, significantly lower than experience with ARCM (80.0% of cardiologists, P<0.001, and 58.5% of leading oncologists, P=0.009, respectively). Senior cardiologists reported less experience with ICIAM compared with their young counterparts (18.6% vs. 38.5%, P=0.018). Of the 20 hospitals providing immunotherapy, 12 (60%) reported \"no consultation\" between the cardiology and oncology departments, and only 5 hospitals (25%) had matching answers for consultation after ICIAM onset between these departments. Conversely, only 4 hospitals (20%) answered \"no consultation\", and 12 hospitals (60%) had matching answers, for interdepartmental consultation before or after ARCM onset.Conclusions: Compared with ARCM, cardiologists and oncologists had less experience, fewer organized measures in place, and increased interdepartmental collaboration vulnerability with ICIAM. Collaboration between cardiologists and oncologists should be promoted in hospitals.","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 3","pages":"176-182"},"PeriodicalIF":0.0,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Developing a Collaborative Model for Cardiac Rehabilitation　- Linking Hospitals and Local Fitness Centers for Older Adults With Cardiovascular Disease. 开发心脏康复的协作模式——将医院和地方健身中心连接起来，为患有心血管疾病的老年人服务。

Circulation reports Pub Date : 2025-02-04 eCollection Date: 2025-03-10 DOI: 10.1253/circrep.CR-24-0169

Takuya Ozeki, Akihiro Hirashiki, Kakeru Hashimoto, Ikue Ueda, Tatsuya Yoshida, Takahiro Kamihara, Manabu Kokubo, Shigeru Sakakibara, Masaki Wada, Yoshihisa Hirakawa, Hitoshi Kagaya, Susumu Suzuki, Mitsutaka Makino, Hidenori Arai, Atsuya Shimizu

{"title":"Developing a Collaborative Model for Cardiac Rehabilitation　- Linking Hospitals and Local Fitness Centers for Older Adults With Cardiovascular Disease.","authors":"Takuya Ozeki, Akihiro Hirashiki, Kakeru Hashimoto, Ikue Ueda, Tatsuya Yoshida, Takahiro Kamihara, Manabu Kokubo, Shigeru Sakakibara, Masaki Wada, Yoshihisa Hirakawa, Hitoshi Kagaya, Susumu Suzuki, Mitsutaka Makino, Hidenori Arai, Atsuya Shimizu","doi":"10.1253/circrep.CR-24-0169","DOIUrl":"10.1253/circrep.CR-24-0169","url":null,"abstract":"Background: Cardiac rehabilitation (CR) is a comprehensive program designed to help cardiac patients reintegrate into social life. The maintenance phase (phase III) is typically conducted in hospitals or at local exercise facilities, depending on individual lifestyles. Effective collaboration between hospitals and local exercise facilities is essential for maintaining CR in older adults with cardiovascular disease (CVD), but several barriers hinder this linkage.Methods and results: Since 2022, the Aichi Health Plaza has maintained CR by developing a unique collaboration handbook (the Cardiac Rehabilitation Exercise Facility Cooperation Medical Institutions [CREpas] handbook). A collaboration system was established with the Department of Cardiology at the National Center for Geriatrics and Gerontology, facilitating seamless transitions through referrals after outpatient center-based CR. Partnerships included methods for information sharing, such as a collaboration diary, training records, occasional telephone calls and emails, and biannual information exchange meetings. A total of 18 collaboration patients was enrolled, and no severe adverse events occurred during exercise. However, 11 (61%) of the 18 patients discontinued the program for various reasons.Conclusions: Transferring CR from hospitals to fitness centers is crucial for older adults with CVD. While safety was ensured at fitness centers, program interruptions highlight the need for addressing barriers to continuity. Seamless healthcare transitions for older CVD patients remain a key challenge in the context of the heart failure pandemic and require further discussion.","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 3","pages":"154-159"},"PeriodicalIF":0.0,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Myocardial T1 Mapping, Left Ventricular Parameters, and Cardiac Biomarkers in Wild-Type Transthyretin Amyloid Cardiomyopathy Before and After Tafamidis Treatment. 心肌T1制图、左心室参数和心脏生物标志物在野生型转甲状腺素淀粉样心肌病治疗前后。

Circulation reports Pub Date : 2025-02-01 eCollection Date: 2025-03-10 DOI: 10.1253/circrep.CR-24-0170

Yuki Ikegami, Toshiro Kitagawa, Yoshiharu Sada, Daiki Okamoto, Kotaro Hamamoto, Fuminari Tatsugami, Kazuo Awai, Yukiko Nakano

{"title":"Myocardial T1 Mapping, Left Ventricular Parameters, and Cardiac Biomarkers in Wild-Type Transthyretin Amyloid Cardiomyopathy Before and After Tafamidis Treatment.","authors":"Yuki Ikegami, Toshiro Kitagawa, Yoshiharu Sada, Daiki Okamoto, Kotaro Hamamoto, Fuminari Tatsugami, Kazuo Awai, Yukiko Nakano","doi":"10.1253/circrep.CR-24-0170","DOIUrl":"10.1253/circrep.CR-24-0170","url":null,"abstract":"Background: To further elucidate the clinical implications of myocardial T1 mapping with cardiac magnetic resonance (CMR) in transthyretin amyloid cardiomyopathy (ATTR-CM), we investigated the relationships of native myocardial T1 value (T1native) and extracellular volume fraction (ECV) with left ventricular (LV) parameters and cardiac biomarkers in ATTR-CM patients before and after tafamidis treatment.Methods and results: We studied wild-type ATTR-CM patients who underwent baseline CMR with LV cine and T1 mapping techniques. T1native and ECV were derived from averaged values of base-to-apex LV myocardium. Cardiac biomarkers, including high-sensitivity cardiac troponin T (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), were measured at baseline. In a subset of the patients, follow-up CMR was performed and cardiac biomarkers were remeasured 1 year after initiation of tafamidis treatment. Both T1native (n=66) and ECV (n=50) positively correlated with LV end-diastolic volume index, LV mass index, Ln (hs-cTnT), and Ln (NT-proBNP). T1native correlated negatively with LV ejection fraction. Multivariate analysis showed that Ln (hs-cTnT) independently correlated with increased T1native (β=0.32; P=0.033). In the tafamidis follow-up group, changes in T1native (∆T1native) (n=30) and ECV (n=21) after treatment (follow-up-baseline values) negatively correlated with their baseline values. ∆T1native positively correlated with ∆NT-proBNP concentration (r=0.45; P=0.013).Conclusions: T1native and ECV are comprehensive indicators of LV characteristics in wild-type ATTR-CM patients and may provide imaging-based evidence of meaningful changes after tafamidis treatment.","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 3","pages":"198-206"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890280/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Novel Missense Variant of ZC3H12A in Pulmonary Arterial Hypertension. 肺动脉高压中一种新的错义变异ZC3H12A。

Circulation reports Pub Date : 2025-01-31 eCollection Date: 2025-03-10 DOI: 10.1253/circrep.CR-25-0007

Ryotaro Asano, Makoto Okazawa, Tomohiko Ishibashi, Xin Ding, Keiko Ohta-Ogo, Kotaro Akaki, Saori Umeki-Mizushima, Akiko Yamagishi, Tadakatsu Inagaki, Ai Yaku, Shinya Fujisaki, Takatoyo Kiko, Kinta Hatakeyama, Osamu Takeuchi, Takeshi Ogo, Yoshikazu Nakaoka

引用次数: 0

Costello Syndrome Complicated by Midventricular Obstruction With an Apical Aneurysm. 科斯特洛综合征并发中脑室梗阻并顶动脉瘤。

Circulation reports Pub Date : 2025-01-30 eCollection Date: 2025-03-10 DOI: 10.1253/circrep.CR-24-0165

Junya Tanabe, Kenji Yasuda, Kazuto Yamaguchi, Taiji Okada, Hiroyuki Yoshitomi, Akihiro Endo, Kazuaki Tanabe

引用次数: 0